FARICIMAB-SVOA for Choroidal neovascularisation: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 65 adverse event reports in the FDA FAERS database where FARICIMAB-SVOA was used for Choroidal neovascularisation.
Most Reported Side Effects for FARICIMAB-SVOA
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 453 | 23.7% | 27 | 28 |
| No adverse event | 259 | 13.6% | 0 | 0 |
| Death | 158 | 8.3% | 153 | 1 |
| Visual impairment | 146 | 7.7% | 1 | 15 |
| Eye inflammation | 136 | 7.1% | 0 | 5 |
| Blindness | 127 | 6.7% | 0 | 8 |
| Endophthalmitis | 125 | 6.6% | 1 | 9 |
| Uveitis | 102 | 5.4% | 0 | 12 |
| Vitritis | 90 | 4.7% | 0 | 13 |
| Drug ineffective | 82 | 4.3% | 0 | 3 |
| Vision blurred | 80 | 4.2% | 0 | 10 |
| Iridocyclitis | 76 | 4.0% | 0 | 9 |
| Vitreous floaters | 65 | 3.4% | 0 | 3 |
| Eye pain | 61 | 3.2% | 0 | 10 |
| Retinal haemorrhage | 51 | 2.7% | 0 | 3 |
Other Indications for FARICIMAB-SVOA
Neovascular age-related macular degeneration (725)
Product used for unknown indication (473)
Diabetic retinal oedema (256)
Age-related macular degeneration (117)
Retinal vein occlusion (104)
Macular oedema (77)
Diabetic retinopathy (71)
Macular degeneration (67)
Dry age-related macular degeneration (19)
Retinal neovascularisation (18)
Other Drugs Used for Choroidal neovascularisation
AFLIBERCEPT (2,953)
RANIBIZUMAB (1,364)
FARICIMAB\FARICIMAB-SVOA (306)
BEVACIZUMAB (302)
BROLUCIZUMAB-DBLL (104)
BROLUCIZUMAB (102)
VERTEPORFIN (42)
AVASTIN (12)
LUCENTIS (11)
TRIAMCINOLONE ACETONIDE (10)